| 2.11 0.04 (1.93%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.98 | 1-year : | 3.45 |
| Resists | First : | 2.55 | Second : | 2.96 |
| Pivot price | 2.23  |
|||
| Supports | First : | 1.89 | Second : | 1.58 |
| MAs | MA(5) : | 2.14 |
MA(20) : | 2.36 |
| MA(100) : | 2.68 |
MA(250) : | 3.18 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 27.2 |
D(3) : | 28.1 |
| RSI | RSI(14): 37.2 |
|||
| 52-week | High : | 5 | Low : | 1.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VTGN ] has closed above bottom band by 31.3%. Bollinger Bands are 18.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.13 - 2.14 | 2.14 - 2.15 |
| Low: | 2.01 - 2.02 | 2.02 - 2.03 |
| Close: | 2.09 - 2.11 | 2.11 - 2.13 |
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Wed, 19 Mar 2025
Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - Stock Titan
Fri, 28 Feb 2025
Is Vistagen Therapeutics (NASDAQ:VTGN) In A Good Position To Invest In Growth? - simplywall.st
Fri, 14 Feb 2025
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
Fri, 14 Feb 2025
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication (NASDAQ:VTGN) - Seeking Alpha
Thu, 13 Feb 2025
VistaGen Therapeutics Inc Q3 Loss Increases, But Beats Estimates - Nasdaq
Thu, 13 Feb 2025
Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 2.022e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.269e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 461.5 % |
| Return on Equity (ttm) | -29.6 % |
| Qtrly Rev. Growth | 698000 % |
| Gross Profit (p.s.) | -76.97 |
| Sales Per Share | -82.65 |
| EBITDA (p.s.) | 1.24643e+006 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.41 |
| Dividend | 0 |
| Forward Dividend | 594670 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|